Addex' Dipraglurant Named as one of the "Top 10 Neuroscience

Addex' Dipraglurant Named as one of the "Top 10 Neuroscience Projects
to Watch" by Windhover and Virginia Herndon 
GENEVA -- (Marketwire) -- 11/27/12 --  Addex Therapeutics / Addex'
Dipraglurant Named as one of the "Top 10 Neuroscience Projects to
by Windhover and Virginia Herndon . Processed and transmitted
by Thomson Reuters ONE. The issuer is solely responsible for the
content of this announcement. 
(SIX: ADXN), a leading company pioneering allosteric modulation-based
drug discovery and development, announced today that
its lead
program, dipraglurant has been named by Windhover and Virginia
as  one of  the Top  10 Neuroscience Projects  to Watch.
Addex recently reported
positive    data    from    a    Phase   2a
clinical   study   of dipraglurant
(  in 
Parkinson's  disease  (PD)  patients  suffering from
levodopa-induced  dyskinesia  (LID).  Dr  Bharatt Chowrira, CEO at
Addex will be presenting the dipraglurant program at the Windhover's
Area  Partnerships meeting  taking place  on November 
28-30, 2012 at the Westin
Copley   Hotel   in   Boston.    The 
presentation  is  scheduled  for November
29(th), 2012 at 1:40PM EST. 
"We  are honored by this recognition  and excited by dipraglurant's
potential to transform the lives of Parkinson's disease patients,"
said Dr. Bharatt Chowrira,
CEO  at Addex. "There is no  approved
treatment for dyskinesia, underscoring the huge unmet medical need in
patients suffering from this debilitating condition.
has  the  potential  to  be  first-in-class  oral  small
treatment  that can  change the  treatment paradigm  for
Parkinson's disease. We look forward to rapidly advancing this
Companies selected for the Top 10 Neuroscience Projects to Watch
honor have been
screened  against a strict set of criteria  and
represent what is considered the most  attractive  neuroscience 
opportunities  the  industry  has to offer. The
selection  of 
dipraglurant  as  one  of  the  Top  10 Neuroscience Projects met
rigorous criteria, including: unmet medical need, market potential,
diversity of indications,  strong science, and  multi-level
partnering opportunities (biotech
and pharma). 
About Dipraglurant 
Dipraglurant  is  an  or
al,  small  molecule  allosteric modulator
that inhibits
selectively  the metabotropic glutamate receptor 5
(mGluR5), a Class C G-Protein
Coupled  Receptor (GPCR), with
potential to be used in combination with levodopa
or  dopamine
agonists or as a  standalone treatment for PD-LID, PD-related
symptoms,  non-motor symptoms  of PD  and other  movement
disorders. Data from a recent Phase 2a show that dipraglurant met the
primary objective of the study by exhibiting   a   good   safety  
and  tolerability  profile.  Dipraglurant also
demonstrated  a
statistically  significant reduction  in LID  severity with both
and  100mg doses.  Dipraglurant  appears  to  reduce  dystonia
severity in addition to chorea, the two major LID components. 
In  a double-blind, placebo-controlled study conducted in the US and
Europe, the primary objective was to demonstrate safety and
tolerability in PD-LID patients.
In  addition,  the  trial  was 
designed  to  evaluate exploratory efficacy as a secondary  
objective.   Efficacy  was  measured  using  the  modified
Involuntary  Movement  Scale  (mAIMS),  patient  diaries 
documenting "off-time"
(impaired voluntary movement), "on-time" (with
or without dyskinesia) and sleep.
Additional  endpoints  include  the
 Unified  Parkinson's  Disease  Rating Scale
(UPDRS),  the Clinician
& Patient Global Impression of Change (CGIC & PGIC), and an 
evaluation of  the patients'  mood using  the Hospital  Anxiety &
Score. The trial was supported by a grant from The Michael
J. Fox Foundation for Parkinson's Research. 
A  successful treatment for  PD-LID would change  the way Parkinson's
disease is treated,  by enabling physicians to use  the most
effective drug for Parkinson's
disease - levodopa - earlier and more
aggressively, according to market research
carried  out by
Datamonitor for Addex.  In addition, based on robust
data,  potential label  expansions for  dipraglurant
include:  PD motor symptoms
and/or  non-motor symptoms,  like
co-morbid  anxiety and  depression, as well as non-parkinsonian
While  dipraglurant  has  broad  potential  for  treating 
Parkinson's and other
diseases,  the most  direct path  to market  is
treatment  of PD-LID. No drug is approved  for PD-LID and LID has 
been identified by the regulatory authorities,
patient  advocacy
groups, such as The Michael J. Fox Foundation, and key
leaders as a very important unmet medical need. The potential
market opportunity
for  dipraglurant  in  Parkinson's  disease  is 
well  in  excess of $1 billion,
according  to Datamonitor. Potential
label expansions could more than double the peak sales potential for
About Dyskinesia & PD 
PD  is a  chronic, progressive  neurological disorder  that affects 
one in 100
people  over  the  age  60 but  as young as 18.
Approximately 7.5 million people
worldwide  are suffering from this
neurodegenerative disorder. The most commonly
administered  and "gold
standard" drug to treat Parkinson's symptoms is levodopa
called  L-dopa),  which  helps  restore  levels  of  dopamine, a
messenger  in the  brain. Following  prolonged use, 
approximately 80 percent of patients  treated  with  levodopa  will 
develop  uncontrollable movements, i.e.
dyskinesias,  a  major 
source  of  disability  in  their  lives. To learn about
listen to this podcast  ( featuring Dr.
and  produced by The Michael J. Fox  Foundation for
Parkinson's Research or find
additional information on PD at the
Foundation's website ( 
mGluR5 inhibition 
There  is  increasingly  convincing  evidence  that  mGluR5 
inhibition may be a valuable   new  strategy  for  treating  a 
number  of  important  diseases and
conditions,  such  as 
Parkinson's  disease,  PD-LID, anxiety, depression, pain,
dyskinesia, addiction, autism  and Fragile X  syndrome. With regards
to Parkinson's  disease,  recent  clinical  and  preclinical  evidence
suggest that
mGluR5  inhibition may  have an  effect on  parkinsonian
motor  symptoms as well
dyskinesia.   mGluR5  is  found  in  regions 
of  the brain considered to be key control  points in the neuronal
movement circuits affected by abnormal signaling
by  the
neurotransmitter glutamate  in PD. Perturbations  in glutamate
(along  with  disruptions  in  dopaminergic  signaling) 
are  believed  to be an underlying  cause  of  movement  disorders 
like  Parkinson's  disease. As such,
inhibiting  mGluR5  could  act 
to  re-establish  normal  movement  via  a non-dopaminergic 
mechanism.  Separately,  preclinical  findings  also suggest that
mGluR5  inhibitors may be neuroprotective and  may, therefore, hold
potential as disease modifying agents that can slow or prevent
progression of PD. 
Addex   Therapeutics   (  discovers  and
develops  an emerging class of small molecule drugs, called
allosteric modulators, which have
the  potential to be more specific
and confer significant therapeutic advantages
over  conventional
"orthosteric" small molecule or biological drugs. The Company
its proprietary discovery platform to address receptors and other
that  are recognized as attractive targets  for modulation
of important diseases
with unmet medical needs. The Company's two
lead products are being investigated
in   Phase  2 clinical  testing:
 dipraglurant  (ADX48621,  an  mGluR5 negative
allosteric  modulator
or NAM)  is being developed  by Addex to treat Parkinson's
levodopa-induced  dyskinesia  (PD-LID);  and  ADX71149 (mGluR2
allosteric  modulator or PAM)  is being developed  in
collaboration with Janssen
Pharmaceuticals  Inc.  to  treat 
schizophrenia  and  anxiety  seen  in patients
suffering  from  major
 depressive  disorder.  Addex  also  is advancing several
 programs including: GABA-BR PAM for spasticity in MS, OAB and
disorders;  mGluR4  PAM  for  Parkinson's,  MS,  anxiety  and
other diseases. In addition,  Addex  is  applying  its  proprietary 
discovery platform to identify
highly  selective and potent
allosteric modulators of  a number of both GPCR and non-GPCR  targets
that are  implicated in diseases  of significant unmet medical
Disclaimer:  The foregoing  release may  contain forward-looking
statements that
can   be  identified  by  terminology  such  as  "not 
approvable", "continue",
"believes",  "believe", "will", "remained
open  to exploring", "would", "could",
or  similar expressions,  or
by  express or  implied discussions regarding Addex
formerly  known  as,  Addex  Pharmaceuticals,  its business, the
potential  approval  of  its  products  by  regulatory authorities,
or regarding
potential  future revenues  from such  products. Such
forward-looking statements
reflect  the current views of Addex
Therapeutics regarding future events, future
economic  performance or
prospects, and, by  their very nature, involve inherent
risks  and
uncertainties, both  general and specific,  whether known or
and/or  any other factor that may  materially differ from
the plans, objectives,
expectations,  estimates and  intentions
expressed  or implied  in such forward-looking  statements. Such may
in particular cause actual results with allosteric modulators of
mGluR2, mGluR4, mGluR5, GABA-BR or other therapeutic targets to be
materially  different  from  any  future  results,  performance  or
expressed  or  implied  by  such  statements.  There 
can  be  no guarantee that
allosteric  modulators of mGluR2, mGluR4, 
mGluR5, GABA-BR or other therapeutics
targets  will be approved for
sale in any market or by any regulatory authority.
Nor  can there  be
any  guarantee that  allosteric modulators of mGluR2, mGluR4,
 GABA-BR or other therapeutic targets will achieve any particular
of  revenue (if  any) in  the future.  In particular, 
management's expectations
regarding  allosteric  modulators  of 
mGluR2,  mGluR4, mGluR5, GABA-BR or other
therapeutic targets could
be affected by, among other things, unexpected actions
by   our 
partners,  unexpected  regulatory  actions  or  delays  or
regulation  generally; unexpected  clinical trial 
results, including unexpected
new  clinical data and unexpected
additional analysis of existing clinical data;
competition   in 
general;  government,  industry  and  general  public
pressures;  the  company's  ability  to  obtain  or  maintain
 patent  or other
proprietary  intellectual property protection.
Should one or more of these risks
or  uncertainties materialize, or
should underlying assumptions prove incorrect,
actual  results may
vary materially  from those anticipated, believed, estimated
expected.  Addex  Therapeutics  is  providing  the information in
this press
release  as of  this date  and does  not undertake  any
obligation to update any forward-looking  statements contained in 
this press release  as a result of new information, future events or
otherwise, except as may be required by applicable
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Addex Therapeutics via Thomson Reuters ONE 
Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
Press spacebar to pause and continue. Press esc to stop.